StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Each row shows where TLRY sits in our scored universe today on a single observational measurement. P85 means TLRY ranks above 85% of peers on that factor right now. Percentile rankings are descriptive — they are not buy/sell signals or quality judgments. Universe refreshed every 60 seconds.
Today's volume vs prior session average.
Absolute daily price move vs peers.
24h article count relative to the universe.
AI-classified polarity of recent news.
Today's dollar turnover (volume × VWAP).
Signed daily return vs the rest of the universe.
Stonvex publishes percentile measurements as observational data only. Nothing here constitutes a recommendation, prediction, or advice about whether to buy, sell, or hold any security. Stonvex is not a registered investment advisor.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-08 | $5.65 | $5.56 | -1.59% | 4.4M |
| 05-11 | $5.50 | $5.51 | +0.18% | 3.6M |
| 05-12 | $5.46 | $5.41 | -0.92% | 2.8M |
| 05-13 | $5.35 | $5.46 | +2.06% | 3.3M |
| 05-14 | $5.44 | $5.50 | +1.10% | 2.8M |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
| Metric | Q1 2026 2026-02-28 | Q4 2025 2025-11-30 | Q3 2025 2025-08-31 | Annual 2025 2025-05-31 |
|---|---|---|---|---|
Revenue | $633.74M | $427.01M | $209.50M | $821.31M |
Operating Income | $-46.57M | $-20.19M | $2.09M | $-2.28B |
Net Income | $-71.83M | $-45.25M | $-322.00K | $-2.19B |
EPS (Diluted) | $-0.65 | $-0.42 | $0.00 | $-2.46 |
Total Assets | $2.07B | $2.10B | $2.08B | $2.07B |
Total Liabilities | $549.12M | $552.09M | $561.99M | $584.75M |
Cash & Equivalents | $204.62M | $246.70M | $264.83M | $221.67M |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | $-127.52M |
Shares Outstanding | 116.55M | 116.52M | 1.12B | 106.07M |
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mainly from alcohol.